AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 272 min read$KNSA

A drug for inflammation around the heart is expected to bring in $1.045-$1.050 billion this year, Kiniksa says.

Kiniksa Pharmaceuticals (KNSA) reported Q3 2026 revenue of $286.0M, up from $180.9M in Q3 2025, driven by its drug ARCALYST. The company raised its 2026 revenue guidance for ARCALYST to $1.045B-$1.050B. Kiniksa also provided updates on its pipeline, including KPL-387 and KPL-1161. Net income for Q3 2026 was $47.3M, compared to $18.4M in Q3 2025.

Original reporting
stocktitan.net
Published Oct 27, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KNSA
Bullish
high confidence
Mentioned
$KNSA
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$KNSABullishHigh
01

Why it matters

The guidance lift reflects strong commercial adoption and may drive near‑term buying interest.

02

Market read

Guidance upgrade is a primary catalyst for KNSA and may influence biotech sector sentiment.

03

What to watch

Potential reimbursement or safety concerns for ARCALYST could temper upside.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Kiniksa reported Q3 2026 results, highlighted ARCALYST revenue growth, and announced updated full‑year guidance.

Company-level read

Ticker impact

$KNSABullishHigh confidence
Context

Kiniksa Pharmaceuticals raised its 2026 ARCALYST net product revenue guidance to $1.045‑$1.050 billion, up from $980‑$995 million.

Expected impact

likely upward pressure as investors price in higher revenue expectations

Evidence & confidence

Revenue guidance increase of >$50 million is material for a mid‑cap biotech and typically triggers a price rally on the day of release.

Market effects

Sector

Higher ARCALYST sales may boost the broader cardiovascular biotech sector.

Regional

U.S. biotech indices could see modest gains.

Global

Limited to investors tracking U.S. biotech earnings and guidance.

Counterpoint

What could challenge this read

If the guidance increase is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • company
    Kiniksa Pharmaceuticals International plc

    Biopharma developing IL‑1 inhibitors, listed on Nasdaq.

Read at source← All news

StoryKiniksa Pharma posts Q3 revenue of $286 M and lifts 2026 ARCALYST sales outlook to $1.045‑$1.050 B

Also covered by

5 outlets

Related articles

OCT 27
$KNSAHigh

Kiniksa (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa reported Q3 2026 revenue of $286M for ARCALYST, up 58% YoY. The company expects KPL-387 trial data in 2H 2027 and aims for a 2028-2029 launch. ARCALYST penetration in recurrent pericarditis patients reached 23%. Kiniksa forecasts $1B+ in 2026 ARCALYST revenue and is investing in AI-driven patient identification and marketing campaigns. Operating income was $54.2M, net income $47.3M, with $568.8M in cash at quarter-end.

finance.yahoo.com3 min